المؤلفون: Stuart AC; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA., Sico JJ; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.; Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA.; Department of Neurology Service, Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut, USA., Viscoli CM; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA., Tayal AH; Neuroscience Institute, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.; Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA., Inzucchi SE; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA., Ford GA; Division of Medical Sciences, Oxford University, Oxford, UK., Furie KL; The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA., Cote R; Department of Neurology, Neurosurgery and Medicine, McGill University, Montreal, Quebec, Canada., Spence JD; University of Western Ontario, London, Ontario, Canada., Tanne D; Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel., Kernan WN; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

المصدر: Stroke and vascular neurology [Stroke Vasc Neurol] 2016 Oct 25; Vol. 1 (3), pp. 108-114. Date of Electronic Publication: 2016 Oct 25 (Print Publication: 2016).

نوع المنشور: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BMJ Country of Publication: England NLM ID: 101689996 Publication Model: eCollection Cited Medium: Print ISSN: 2059-8688 (Print) Linking ISSN: 20598688 NLM ISO Abbreviation: Stroke Vasc Neurol

مواضيع طبية MeSH: Secondary Prevention*, Ischemic Attack, Transient/*prevention & control , Ischemic Stroke/*prevention & control, Aged ; Anticholesteremic Agents/therapeutic use ; Antihypertensive Agents/therapeutic use ; Biomarkers/blood ; Blood Coagulation/drug effects ; Blood Pressure ; Cholesterol, LDL/blood ; Double-Blind Method ; Europe ; Female ; Fibrinolytic Agents/therapeutic use ; Humans ; Hypoglycemic Agents/therapeutic use ; Insulin Resistance ; Ischemic Attack, Transient/blood ; Ischemic Attack, Transient/diagnosis ; Ischemic Attack, Transient/physiopathology ; Ischemic Stroke/blood ; Ischemic Stroke/diagnosis ; Ischemic Stroke/physiopathology ; Israel ; Male ; Middle Aged ; North America ; Pioglitazone/therapeutic use ; Recurrence ; Risk Assessment ; Risk Factors ; Risk Reduction Behavior ; Time Factors ; Treatment Outcome